Synthetic Data for Pharma AI

Industry Application

Synthetic DataPharma & Life Sciences

The pharmaceutical and life sciences industries sit at a paradoxical intersection: they generate some of the richest, most consequential data on earth — genomic sequences, electronic health records, imaging studies, clinical trial endpoints — yet the regulatory, ethical, and competitive barriers to sharing that data are among the highest of any sector. Synthetic data has emerged as the practical resolution to this paradox, enabling AI development, cross-institutional collaboration, and regulatory submission at a scale that would be impossible with real patient data alone.

Drug Discovery and Molecular Generation

The earliest and most commercially mature application of synthetic data in pharma is de novo molecular generation. Generative models — variational autoencoders, diffusion models, and transformer-based architectures — are trained on known compound libraries such as ChEMBL, PubChem, and proprietary screening collections, then used to synthesize vast libraries of novel candidate molecules with specified target properties: binding affinity, solubility, metabolic stability, and selectivity. Insilico Medicine used this approach to advance INS018_055, an AI-designed fibrosis drug candidate, into Phase II clinical trials by 2024 — a milestone that compressed what would traditionally be a decade of medicinal chemistry into roughly two years. Recursion Pharmaceuticals combines high-content imaging of cellular perturbations with generative augmentation to manufacture millions of synthetic biological phenotype records, effectively industrializing hypothesis generation across its discovery pipeline. NVIDIA's BioNeMo platform, launched broadly in 2024, provides foundation model infrastructure for protein structure prediction, molecular docking, and synthetic SMILES generation, enabling mid-sized biotechs to access capabilities previously restricted to hyperscalers.

Synthetic Control Arms and Clinical Trial Optimization

Clinical trials are the single largest cost center in drug development, averaging $1.3 billion and 10–15 years per approved molecule. Synthetic data is restructuring the economics. Unlearn.ai has pioneered the use of digital twins — synthetic patient records generated by longitudinal disease progression models — to create synthetic control arms for randomized controlled trials. By statistically matching each enrolled patient to a synthetically generated counterfactual, sponsors can reduce the required placebo arm size by 30–50%, accelerating enrollment and cutting costs without sacrificing statistical rigor. The FDA issued draft guidance in 2023 acknowledging the use of synthetic and real-world data as supplementary control data, a regulatory signal that has accelerated adoption. Medidata (Dassault Systèmes) has integrated synthetic patient simulation into its Rave platform, allowing sponsors to stress-test trial protocols against thousands of simulated patient trajectories before a single subject is enrolled — identifying futility risks and optimizing dosing windows at the design stage rather than after expensive failures.

Medical Imaging AI and Diagnostic Models

Training high-performing diagnostic AI requires annotated imaging datasets at a scale that real-world data collection struggles to supply, particularly for rare pathologies. A model that must distinguish 15 subtypes of renal cell carcinoma on CT may encounter only a handful of confirmed cases across any single institution's archive. Synthetic imaging — generated by conditional GANs, latent diffusion models, and physics-based simulation — addresses this directly. Syntho and Segmed have built platforms specifically for synthetic medical imaging augmentation, generating privacy-preserving MRI, CT, and pathology slide images that preserve clinically relevant morphological features while eliminating re-identification risk. Siemens Healthineers and GE HealthCare have both deployed internal synthetic imaging pipelines to train and validate FDA-cleared diagnostic models. At the research frontier, Google DeepMind's medical imaging division has published work demonstrating that diffusion-model-generated synthetic retinal fundus images can augment real datasets to improve diabetic retinopathy detection accuracy in low-prevalence subgroups — precisely the populations where real data is scarcest and model failures are most consequential.

Synthetic EHR Data for Real-World Evidence and Pharmacovigilance

Post-market safety surveillance and real-world evidence generation both depend on access to longitudinal patient records across large, diverse populations. The challenge is that such data is siloed in health systems governed by HIPAA, GDPR, and equivalent frameworks, making cross-institutional sharing legally complex and commercially sensitive. Syntegra has addressed this by training generative models directly on real EHR data from health system partners, producing synthetic patient populations that preserve the statistical structure, temporal correlations, and comorbidity patterns of the source population without retaining any individual's record. Health systems can then share synthetic datasets with biopharma partners, academic researchers, and public health agencies freely. MDClone, a health analytics company deployed across major US academic medical centers, uses a similar approach to enable researchers to query synthetic patient cohorts — receiving statistically valid aggregate results without ever accessing the underlying real records. For pharmacovigilance, synthetic adverse event datasets allow safety teams to train signal detection algorithms on rare event patterns that would require years of surveillance to accumulate organically.

Rare Disease Research and Federated Learning Augmentation

Rare diseases — affecting fewer than 200,000 patients in the US by FDA definition — present the most acute data scarcity problem in medicine. A sponsor developing a therapy for a condition affecting 3,000 patients globally cannot assemble the training datasets needed for modern AI-assisted trial design or biomarker discovery through conventional means. Synthetic data augmentation has become the standard mitigation strategy. Federated learning consortia, such as those organized under the European Health Data Space and the NIH's All of Us Research Program, increasingly pair federated training with synthetic data generation: each participating institution trains a local generative model, shares only the model weights, and the aggregated model is then used to generate a central synthetic dataset large enough to train the downstream diagnostic or predictive model. This architecture keeps real patient data within institutional boundaries while producing a shared synthetic asset that no single institution could have generated alone.

Applications & Use Cases

De Novo Molecular Generation

Generative models trained on compound libraries synthesize novel drug candidates with specified pharmacological properties — binding affinity, ADMET profiles, selectivity — dramatically expanding the searchable chemical space beyond what wet-lab screening can reach. Companies like Insilico Medicine and Recursion Pharmaceuticals have advanced AI-designed molecules into clinical trials using this approach.

Synthetic Control Arms

Digital twin models generate synthetic patient trajectories that serve as statistical controls in randomized clinical trials, reducing required placebo arm sizes by 30–50%. Unlearn.ai's platform has been deployed in Phase II and Phase III trials across neurology, oncology, and rare disease indications, with explicit FDA guidance acknowledging the methodology.

Medical Imaging Augmentation

Conditional diffusion models and GANs generate synthetic MRI, CT, PET, and digital pathology images — annotated with ground-truth labels — to address class imbalance in rare pathology training sets. Siemens Healthineers and GE HealthCare use synthetic imaging pipelines internally to train and validate FDA-cleared diagnostic AI without relying solely on de-identified real scans.

Synthetic EHR Generation for RWE

Generative models trained on real electronic health records produce statistically faithful synthetic patient populations that can be shared across institutional and regulatory boundaries. Syntegra and MDClone enable biopharma sponsors to conduct real-world evidence studies and cohort analyses on synthetic data, bypassing the legal friction of HIPAA data sharing agreements.

Pharmacovigilance Signal Detection

Synthetic adverse event datasets augment rare safety signals — anaphylaxis, severe hepatotoxicity, drug-induced arrhythmia — enabling AI-powered pharmacovigilance systems to detect patterns that would require years of passive surveillance to accumulate from spontaneous reporting alone. Regulators at the FDA and EMA have begun exploring synthetic data as a tool for proactive safety signal simulation.

Federated Learning & Rare Disease Research

In rare disease contexts, federated consortia pair distributed model training with local synthetic data generation. Each institution trains a generative model on its local cohort, shares model weights, and the aggregated model produces a centralized synthetic dataset large enough to train downstream predictive models — keeping real patient records within institutional walls while enabling collaborative AI development at scale.

Key Players

Insilico Medicine — Pioneer in AI-driven drug discovery, using generative chemistry models to design novel molecules; advanced INS018_055, an AI-designed IPF drug candidate, into Phase II clinical trials by 2024.
Unlearn.ai — Builds digital twin models that generate synthetic patient trajectories for use as synthetic control arms in Phase II/III clinical trials; has FDA and EMA engagement on methodology validation.
Syntegra — Trains large generative models on real EHR data from health system partners to produce high-fidelity synthetic patient datasets for biopharma real-world evidence studies and public health research.
Recursion Pharmaceuticals — Combines high-content cellular imaging with generative data augmentation to produce millions of synthetic biological phenotype records, powering a vertically integrated AI drug discovery engine.
NVIDIA (BioNeMo) — Provides foundation model infrastructure for synthetic molecular and protein data generation, including SMILES synthesis, protein structure prediction, and molecular docking simulation at scale.
MDClone — Deployed across major US academic medical centers, enables researchers to query synthetic patient cohorts derived from real EHR data, returning statistically valid results without exposing individual records.
Medidata (Dassault Systèmes) — Integrates synthetic patient simulation into its clinical trial platform, allowing sponsors to model thousands of synthetic patient trajectories to optimize trial design before enrollment begins.
BenevolentAI — Uses knowledge graph–based AI combined with synthetic data augmentation to identify novel drug targets and repurposing opportunities across rare and complex diseases.

Challenges & Considerations

Fidelity vs. Privacy Trade-off — Synthetic patient data must be statistically similar enough to real data to be scientifically useful, but dissimilar enough to provide genuine privacy protection. Achieving both simultaneously is technically difficult, and current evaluation frameworks — membership inference attacks, attribute disclosure tests — are not yet standardized across the industry.
Regulatory Acceptance and Validation — While the FDA has issued guidance acknowledging synthetic and real-world data in specific contexts (notably synthetic control arms), comprehensive regulatory frameworks for synthetic data use in primary endpoints, NDA submissions, and pharmacovigilance reporting remain under development. Sponsors face uncertainty about what validation evidence is required.
Rare Event Representation — Generative models trained on real-world data inherit its class imbalances. Synthetic data generation for rare adverse events, uncommon pathological subtypes, or underrepresented patient populations risks amplifying existing biases rather than correcting them, requiring careful conditioning and post-hoc validation.
Downstream Model Validation — A diagnostic AI or trial simulation model trained on synthetic data must ultimately be validated against real patient outcomes. Establishing that synthetic-data-trained models generalize reliably to real-world performance — and convincing regulators of this — requires rigorous bridging studies that add time and cost back into the development process.
Intellectual Property and Data Provenance — When synthetic data is generated from proprietary compound libraries, proprietary EHR datasets, or third-party genomic databases, questions arise about who owns the synthetic output and what licensing obligations attach to it. These questions are largely unresolved in contract law and becoming increasingly contested as synthetic datasets gain commercial value.
Genomic Data Complexity — High-dimensional genomic and proteomic data presents particular challenges for generative models: the feature space is orders of magnitude larger than tabular EHR data, causal relationships between variants and phenotypes are poorly understood, and the consequences of synthetic errors — spurious variant associations, missed epistatic interactions — can cascade through downstream discovery workflows in ways that are difficult to detect.